Venous thromboembolism: A clinical review

Postgraduate Medicine

Volumn 122, Issue 2, 2010, Pages 54-65

  Osinbowale, Olusegun ^a   Ali, Lobna ^a   Chi, Yung Wei ^a  

^a JOHN OCHSNER HEART AND VASCULAR INSTITUTE   (United States)

Author keywords

Anticoagulation; Deep vein thrombosis; Heparin; Low molecular weight heparin; Pulmonary embolism; Venous thromboembolism; Warfarin

Indexed keywords

ANTICOAGULANT AGENT; ANTINEOPLASTIC AGENT; ANTITHROMBIN; ARGATROBAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; BLOOD CLOTTING FACTOR 5 LEIDEN; D DIMER; DABIGATRAN; ENOXAPARIN; ESTROGEN; FIBRIN DEGRADATION PRODUCT; FONDAPARINUX; GESTAGEN; HEPARIN; HIRULOG; HOMOCYSTEINE; LEPIRUDIN; LOW MOLECULAR WEIGHT HEPARIN; ORAL CONTRACEPTIVE AGENT; PHOSPHOLIPID ANTIBODY; PROTEIN C; PROTEIN S; PROTHROMBIN; RIVAROXABAN; THROMBIN INHIBITOR; THROMBOPLASTIN; WARFARIN; FIBRINOLYTIC AGENT;

ACTIVATED PROTEIN C RESISTANCE; AGE; ANTICOAGULATION; ANTIPHOSPHOLIPID SYNDROME; ANTITHROMBIN DEFICIENCY; ARTHROSCOPIC SURGERY; BED REST; BLEEDING; BLOOD ANALYSIS; BLOOD CLOT LYSIS; CANADA; CENTRAL VENOUS CATHETERIZATION; COMPUTER ASSISTED TOMOGRAPHY; DEEP VEIN THROMBOSIS; DRUG APPROVAL; DRUG RESEARCH; ECHOGRAPHY; ELECTROCARDIOGRAPHY; ENDOTHELIAL DYSFUNCTION; EUROPEAN UNION; FOOD AND DRUG ADMINISTRATION; HEMOSTASIS; HEPARIN INDUCED THROMBOCYTOPENIA; HIP ARTHROPLASTY; HIP FRACTURE; HOMOCYSTINURIA; HORMONE SUBSTITUTION; HUMAN; HYPERCOAGULABILITY; HYPERHOMOCYSTEINEMIA; IMMOBILIZATION; INTERMITTENT PNEUMATIC COMPRESSION DEVICE; LAPAROSCOPIC SURGERY; LUNG ANGIOGRAPHY; LUNG EMBOLISM; LUNG SCINTISCANNING; MALIGNANT NEOPLASTIC DISEASE; MEDICAL HISTORY; MORBIDITY; MORTALITY; MULTIPLE TRAUMA; NUCLEAR MAGNETIC RESONANCE IMAGING; OBESITY; PARTIAL THROMBOPLASTIN TIME; PATHOPHYSIOLOGY; PATIENT MONITORING; PELVIS FRACTURE; PHYSICAL EXAMINATION; PREGNANCY; PROTEIN C DEFICIENCY; PROTEIN S DEFICIENCY; REVIEW; RISK FACTOR; SENSITIVITY AND SPECIFICITY; SPINAL CORD INJURY; THROMBECTOMY; THROMBOPHILIA; TOTAL KNEE REPLACEMENT; TREATMENT DURATION; TREATMENT INDICATION; UNITED STATES; VARICOSIS; VENA CAVA FILTER; VENOUS THROMBOEMBOLISM; VEIN THROMBOSIS;

ANTICOAGULANTS; FIBRINOLYTIC AGENTS; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; PULMONARY EMBOLISM; RISK FACTORS; VENA CAVA FILTERS; VENOUS THROMBOEMBOLISM; VENOUS THROMBOSIS; WARFARIN;

EID: 77950348481     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2010.03.2122     Document Type: Review

References (55)

1. Ho WK, Hankey GJ, Eikelboom JW. The incidence of venous thromboembolism: a prospective, community-based study in Perth, Western Australia. Med J Aust. 2008;189(3):144-147.
2. Access Economics. The burden of venous thromboembolism in Australia. Report for the Australia and New Zealand Working Party on the Management and Prevention of Venous Thromboembolism. 2008:1-49. http://www.accesseconomics.com.au/publicationsreports/showreport.php?ida161
3. White RH. The epidemiology of venous thromboembolism. Circulation. 2003;107(23 suppl 1):I4-I8.
4. White RH, Zhou H, Romano PS. Incidence of idiopathic deep venous thrombosis and secondary thromboembolism among ethnic groups in California. Ann Intern Med. 1998;128(9):737-740.
5. Goldhaber SZ. Pulmonary embolism. Lancet. 2004;363(9417):1295-1305.
6. Geerts WH, Bergqvist D, Pineo GF, et al; American College of Chest Physicians. Prevention of venous thromboembolism: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):381S-453S.
7. Blann AD, Lip GY. Venous thromboembolism. BMJ. 2006;332(7535):215-219.
8. Anderson FA Jr, Wheeler HB. Physician practices in the management of venous thromboembolism: a community-wide survey. J Vasc Surg. 1992;16(5):707-714.
9. Anderson FA Jr, Spencer FA. Risk factors for venous thromboembolism. Circulation. 2003;107(23 suppl 1):I-9-I-16.
10. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):338S-400S.
11. Geerts WH, Code KI, Jay RM, Chen E, Szalai JP. A prospective study of venous thromboembolism after major trauma. N Engl J Med. 1994;331(24):1601-1606.
12. Bowcock SJ, Rassam SM, Ward SM, Turner JT, Laffan M. Thromboembolism in patients on thalidomide for myeloma. Hematology. 2002;7(1):51-53.
13. Osman K, Comenzo R, Rajkumar SV. Deep venous thrombosis and thalidomide therapy for multiple myeloma. N Engl J Med. 2001;344(25):1951-1952.
14. Zangari M, Anaissie E, Barlogie B, et al. Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy. Blood. 2001;98(5):1614-1615.
15. Bergqvist D, Lowe G. Venous thromboembolism in patients undergoing laparoscopic and arthroscopic surgery and in leg casts. Arch Intern Med. 2002;162(19):2173-2176.
16. Lindberg F, Rasmussen I, Siegbahn A, Bergqvist D. Coagulation activation after laparoscopic cholecystectomy in spite of thromboembolism prophylaxis. Surg Endosc. 2000;14(9):858-861.
17. Lidegaard Ø, Edström B, Kreiner S. Oral contraceptives and venous thromboembolism: a five-year national case-control study. Contraception. 2002;65(3):187-196.
18. Aaro LA, Juergens JL. Thrombophlebitis associated with pregnancy. Am J Obstet Gynecol. 1971;109(8):1128-1136.
19. Hogberg U. Maternal deaths in Sweden, 1971-1980. Acta Obstet Gynecol Scand. 1986;65(2):161-167.
20. Grady D, Applegate W, Bush T, Furberg C, Riggs B, Hulley SB. Heart and Estrogen/progestin Replacement Study (HERS): design, methods, and baseline characteristics. Control Clin Trials. 1998;19(4):314-335.
21. Hoøbraaten E, Qvigstad E, Arnesen H, Larsen S, Wickstrøm E, Sandset PM. Increased risk of recurrent venous thromboembolism during hormone replacement therapy-results of the randomized, double-blind, placebo-controlled estrogen in venous thromboembolism trial (EVTET). Thromb Haemost. 2000;84(6):961-967.
22. Lundgren R, Sundin T, Colleen S, et al. Cardiovascular complications of estrogen therapy for nondisseminated prostatic carcinoma. A preliminary report from a randomized multicenter study. Scand J Urol Nephrol. 1986;20(2):101-105.
23. Warlow C, Ogston D, Douglas AS. Venous thrombosis following strokes. Lancet. 1972;1(7764):1305-1306.
24. Samama MM. An epidemiologic study of risk factors for deep vein thrombosis in medical outpatients: the Sirius study. Arch Intern Med. 2000;160(22):3415-3420.
25. Heit JA, O'Fallon WM, Petterson TM, et al. Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a populationbased study. Arch Intern Med. 2002;162(11):1245-1248.
26. Gibbs NM. Venous thrombosis of the lower limbs with particular reference to bed-rest. Br J Surg. 1957;45(191):209-236.
27. Goldhaber SZ, Grodstein F, Stampfer MJ, et al. A prospective study of risk factors for pulmonary embolism in women. JAMA. 1997;277(8):642-645.
28. Stein PD, Terrin ML, Hales CA, et al. Clinical, laboratory, roentgenographic, and electrocardiographic findings in patients with acute pulmonary embolism and no pre-existing cardiac or pulmonary disease. Chest. 1991;100(3):598-603.
29. Wells PS, Anderson DR, Bormanis J, et al. Value of assessment of pretest probability of deep-vein thrombosis in clinical management. Lancet. 1997;350(9094):1795-1798.
30. Wells PS, Ginsberg JS, Anderson DR, et al. Use of a clinical model for safe management of patients with suspected pulmonary embolism. Ann Intern Med. 1998;129(12):997-1005.
31. Dunn KL, Wolf JP, Dorfman DM, Fitzpatrick P, Baker JL, Goldhaber SZ. Normal D-dimer levels in emergency department patients suspected of acute pulmonary embolism. J Am Coll Cardiol. 2002;40(8):1475-1478.
32. Qaseem A, Snow V, Barry P, et al; Joint American Academy of Family Physicians/American College of Physicians Panel on Deep Venous Thrombosis/Pulmonary Embolism. Current diagnosis of venous thromboembolism in primary care: a clinical practice guideline from the American Academy of Family Physicians and the American College of Physicians. Ann Fam Med. 2007;5(1):57-62.
33. Kanne JP, Lalani TA. Role of computed tomography and magnetic resonance imaging for deep venous thrombosis and pulmonary embolism. Circulation. 2004;109(12 suppl 1):I15-I21.
34. Meaney JF, Weg JG, Chenevert TL, Stafford-Johnson D, Hamilton BH, Prince MR. Diagnosis of pulmonary embolism with magnetic resonance angiography. N Engl J Med. 1997;336(20):1422-1427.
35. Dupas B, el Kouri D, Curtet C, et al. Angiomagnetic resonance imaging of iliofemorocaval venous thrombosis. Lancet. 1995;346(8966):17-19.
36. Miniati M, Pistolesi M, Marini C, et al. Value of perfusion lung scan in the diagnosis of pulmonary embolism: results of the Prospective Investigative Study of Acute Pulmonary Embolism Diagnosis (PISAPED). Am J Respir Crit Care Med. 1996;154(5):1387-1393.
37. Hirsh J, Raschke R. Heparin and low-molecular-weight heparin: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):188S-203S.
38. Hirsh J, Guyatt G, Albers GW, Harrington R, Schünemann HJ; American College of Chest Physicians. Executive summary: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):71S-109S.
39. Kearon C, Kahn SR, Agnelli G, Goldhaber S, Raskob GE, Comerota AJ; American College of Chest Physicians. Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):454S-545S.
40. Jiménez D, Yusen RD, Otero R, et al. Prognostic models for selecting patients with acute pulmonary embolism for initial outpatient therapy. Chest. 2007;132(1):24-30.
41. Aujesky D, Obrosky DS, Stone RA, et al. A prediction rule to identify low-risk patients with pulmonary embolism. Arch Intern Med. 2006;166(2):169-175.
42. Girolami B, Prandoni P, Stefani PM, et al. The incidence of heparininduced thrombocytopenia in hospitalized medical patients treated with subcutaneous unfractionated heparin: a prospective cohort study. Blood. 2003;101(8):2955-2959.
43. Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia: recognition, treatment, and prevention: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest. 2004;126(3 suppl):311S-337S.
44. Lee AY, Levine MN, Baker RI, et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003;349(2):146-153.
45. Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecularweight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002;162(15):1729-1735.
46. Bates SM, Greer IA, Pabinger I, Sofaer S, Hirsh J; American College of Chest Physicians. Venous thromboembolism, thrombophilia, antithrombotic therapy, and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008;133(6 suppl):844S-886S.
47. Kaufman JA, Kinney TB, Streiff MB, et al. Guidelines for the use of retrievable and convertible vena cava filters: report from the Society of Interventional Radiology multidisciplinary consensus conference. J Vasc Interv Radiol. 2006;17(3):449-459.
48. Blann AD, Khoo CW. The prevention and treatment of venous thromboembolism with LMWHs and new anticoagulants. Vasc Health Risk Manag. 2009;5:693-704.
49. Eriksson BI, Dahl OE, Ahnfelt L, et al. Dose escalating safety study of a new oral direct thrombin inhibitor, dabigatran etexilate, in patients undergoing total hip replacement: BISTRO I. J Thromb Haemost. 2004;2(9):1573-1580.
50. Eriksson BI, Dahl OE, Büller HR, et al; BISTRO II Study Group. A new oral direct thrombin inhibitor, dabigatran etexilate, compared with enoxaparin for prevention of thromboembolic events following total hip or knee replacement: the BISTRO II randomized trial. J Thromb Haemost. 2005;3(1):103-111.
51. Eriksson BI, Borris LC, Friedman RJ, et al; RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358(26):2765-2775.
52. Lassen MR, Ageno W, Borris LC, et al; RECORD3 Investigators. Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358(26):2776-2786.
53. Rocha AT, Paiva EF, Lichtenstein A, Milani R Jr, Cavalheiro CF, Maffei FH. Risk-assessment algorithm and recommendations for venous thromboembolism prophylaxis in medical patients. Vasc Health Risk Manag. 2007;3(4):533-553.
54. Tooher R, Middleton P, Pham C, et al. A systematic review of strategies to improve prophylaxis for venous thromboembolism in hospitals. Ann Surg. 2005;241(3):397-415.
55. Motykie GD, Zebala LP, Caprini JA, et al. A guide to venous thromboembolism risk factor assessment. J Thromb Thrombolysis. 2000;9(3):253-262.